ClinicalTrials.gg
RecruitingNCT06387446Updated Sep 24, 2024

Allogeneic Valve Transplantation

An interventional study of Valve transplant in Valve Heart Disease, Valve Disease, Heart and Valve Disease, Aortic, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 30 Days to 50 Years. Per ClinicalTrials.gov, last updated 2024-09-24.

Primary conditionAortic Valve DiseaseRegistry: Heart Valve DiseasesReclassifiedWhy we changed it
Registry
Heart Valve Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Disease
Why
  1. The study's listed conditions name Aortic Valve Disease, a narrower term within Heart Valve Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
30 Days to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 47 studies in Aortic Valve Disease with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Aortic Valve Disease · United States.

Planned enrollment
29th of 31
4 · median 190
Started
2024
with 4 others
No phase
27 of 47
9 open now
Primary completion
2027-06
later than 15 of 22 live
Registered
36th of 47
by date

Among the 47 studies in Aortic Valve Disease with a site in United States, this one is the 29th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2024, is one of 27 with no phase, reaches primary completion later than 15 of the 22 other live ones, and was the 36th registered.

Aortic Valve Disease

234 studies on the registry are indexed under Aortic Valve Disease; 70 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

12 of the 47 studies in Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 30 Days to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Aortic Valve Disease with a site in United States, or all of them as a file.
02

Study summary

Valves will be taken from hearts donated by organ donors, and implanted into patients who need a new heart valve.

Read the detailed description

Heart valves in children and young adults may need replacement or repair. In many children the options for heart valve replacement do not grow as the child grows. A transplanted valve may have the option to grow with time and may reduce the need for multiple operations over a lifetime. This trial will study the outcomes of heartfelt transplant in children and young adults undergoing this procedure. The study will look at outcomes of valve transplant and any potential side effects.

03

Conditions studied

  • Valve Heart Disease
  • Valve Disease, Heart
  • Valve Disease, Aortic

Browse trials for

04

In context

Aortic Valve Disease Reclassified

234 studies on the registry are indexed under Aortic Valve Disease; 70 are open to participants now.

This study's planned enrollment of 4 is below the median of 111 across 125 interventional studies indexed under Aortic Valve Disease.

Browse Aortic Valve Disease studies →

Lead sponsor

Boston Children's Hospital is the lead sponsor of 608 studies on the registry; 147 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Compared within Aortic Valve Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Valve Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
30 Days to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients requiring aortic, pulmonary, mitral or tricuspid valve replacement.
  • Pediatric patients 30 days or older and \< 18 years, and adult patients 18-50 yrs.

    o Particularly patients with significant growth potential

  • Insufficient options are available for valve replacement

    o Patients at risk of immunogenic bio-prosthetic valve failure

  • Discussion with patient /family - option for durable valve rather than traditional prosthesis
  • ABO compatible
  • Patient and family able to travel to BCH within 48 hour time frame or within our organ procurement organization
  • Patients that are able to maintain follow-up at BCH during the duration of the study
  • Patients that are able to provide medical record authorization for 5 year follow-up

Exclusion criteria

Exclusion Criteria

  • Age \< 30 days
  • Irreversible multisystem organ failure; or additive effects of the multiple systems affected making transplant survival unlikely
  • Progressive systemic disease with early mortality (genetic/metabolic, idiopathic, syndromic)
  • Morbid obesity (>35)
  • Diabetes mellitus with evidence of end-organ damage
  • Severe chromosomal, neurologic or syndromic abnormalities
  • condition (DiGeorge, SCID etc.)
  • Active infection
  • History of endocarditis
  • or chronic or C infection
  • within 5 years prior to transplant
  • Severe renal or liver failure
  • Inadequate social support for post-transplant management
  • Recent history of illicit drug, tobacco or alcohol abuse despite trials/assistance to stop behavior
  • Evidence of large stroke with high risk for hemorrhagic conversion
  • Heart transplant recipient
  • Patients that are unable to follow-up during the initial 6 month window
  • Patients that are unable to provide medical record authorization for 5 years
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    Valve transplantation group

    This arm undergoes Allogeneic Valve transplantation

    Procedure: Valve transplant

Interventions

  • ProcedureValve transplant

    Heart valves from an organ donor will be transplanted into recipient

07

What researchers measure

Primary outcomes

  1. Valve Regurgitation

    Heart valve regurgitation by echocardiogram. The degree of regurgitation is read and quantified by an echocardiologist.

    Time frame: One year

  2. Valve Annulus Growth

    Measurement of valve annulus via echocardiogram, CT scan and MRI. This will be quantified by whether or not the annulus continues to increase in size as the subject grows.

    Time frame: One Year

  3. Leaflet Growth

    Measurement of leaflet height via echocardiogram, CT scan and MRI and reviewed by an echocardiologist. This will be analyzed by whether or not the leaflets continue to grow in size, with the subject.

    Time frame: One Year

Secondary outcomes

  1. Ventricular Function

    Ventricular function will be visualized using echocardiogram, measured as ejection fraction as well as shortening fraction and will be determined by an echocardiologist. The factors involved will be the symmetrical squeeze of the ventricles, the ejection fraction, ventricular end systolic and diastolic volume with calculation of stroke volume to come to a surrogate of cardiac output.

    Time frame: One year

  2. Survival

    The number of patients that survive the initial procedure and long term outcomes.

    Time frame: 5 years

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2027, 37 months after the start.

Of 61 interventional studies with no phase under Aortic Valve Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 61. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Apr 29, 2024
StartActual
May 1, 2024
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06387446
Responsible party
Sitaram Emani (Associate Professor of Surgery, Boston Children's Hospital) — Principal investigator
First posted
Apr 29, 2024
Start date
May 1, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Sep 24, 2024

Study contacts

Sitaram Emani, MD
Contact
sitaram.emani@cardio.chboston.org
6173557899
Sitaram Emani, MD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion